# Traws Pharma, Inc.: overview TRAW · Nasdaq · CIK 1130598 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/traw.md) · [Financials](/companies/traw/financials.md) · [Filings](/companies/traw/filings.md) · [Insiders](/companies/traw/insiders.md) Latest reported revenue: [$0](/filings/0001104659-26-043832.md) for Q4 FY2025, three months to 2025-12-31, from the 10-K filed Apr 15, 2026 (XBRL us-gaap:Revenues, accession 0001104659-26-043832). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.1](/filings/0001558370-24-015752.md) | [0.1 d](/filings/0001104659-26-043832.md) | [0.1](/filings/0001104659-26-061779.md) | [2.7](/filings/0001104659-26-097261.md) | [0.0 d](/filings/0001104659-25-110845.md) | [0.0 d](/filings/0001104659-26-043832.md) | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(14975.4%)](/filings/0001104659-25-110845.md) | [(9425.0%) d](/filings/0001104659-26-043832.md) | [(9128.1%)](/filings/0001104659-26-061779.md) | [(45.7%)](/filings/0001104659-26-097261.md) | not reported | not reported | not reported | not reported | | Net margin | % | [(14868.4%)](/filings/0001104659-25-110845.md) | [(53432.1%) d](/filings/0001104659-26-043832.md) | [37701.8%](/filings/0001104659-26-061779.md) | [(33.5%)](/filings/0001104659-26-097261.md) | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.49)](/filings/0001104659-25-110845.md) | not reported | [2.09](/filings/0001104659-26-061779.md) | [(0.11)](/filings/0001104659-26-097261.md) | [(0.34)](/filings/0001104659-25-110845.md) | not reported | [(0.53)](/filings/0001104659-26-061779.md) | [(0.16)](/filings/0001104659-26-097261.md) | | Free cash flow | $m | [(11.5) d](/filings/0001104659-25-110845.md) | [(4.0) d](/filings/0001104659-26-043832.md) | not reported | not reported | not reported | [(2.8) d](/filings/0001104659-26-043832.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure; 9-month figure less the 6-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure; 9-month figure less the 6-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure; 9-month figure less the 6-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure; 9-month figure less the 6-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.2](/filings/0001558370-23-005107.md) | [0.2](/filings/0001558370-24-004525.md) | [0.2](/filings/0001558370-25-004165.md) | [0.2](/filings/0001104659-26-043832.md) | [2.8](/filings/0001104659-26-043832.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(7299.1%)](/filings/0001558370-23-005107.md) | [(8684.5%)](/filings/0001558370-24-004525.md) | [(8981.4%)](/filings/0001558370-25-004165.md) | [(62997.3%)](/filings/0001104659-26-043832.md) | [(640.7%)](/filings/0001104659-26-043832.md) | | Net margin | % | [(7151.8%)](/filings/0001558370-23-005107.md) | [(8391.2%)](/filings/0001558370-24-004525.md) | [(8384.1%)](/filings/0001558370-25-004165.md) | [(73682.7%)](/filings/0001104659-26-043832.md) | [328.7%](/filings/0001104659-26-043832.md) | | Diluted EPS | $ per share | [(0.96)](/filings/0001558370-23-005107.md) | [(0.91)](/filings/0001558370-24-004525.md) | [(22.57)](/filings/0001558370-25-004165.md) | [(35.21)](/filings/0001104659-26-043832.md) | [0.82](/filings/0001104659-26-043832.md) | | Free cash flow | $m | not reported | not reported | [(17.9)](/filings/0001558370-25-004165.md) | [(33.4)](/filings/0001104659-26-043832.md) | [(20.8)](/filings/0001104659-26-043832.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/traw/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2013-07-30 | [Baxter Healthcare SA](/insiders/1582211.md) | 10% owner | Purchase (P) | 330,000 | $15.00 | $5.0m | [Form 4](/filings/0001179110-13-012429.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $1.0m | 1,203,260 | | Added +597,729 | | [Ally Bridge Group (NY) LLC](/funds/1822947.md) | 2026-06-30 | $663.0k | 786,236 | | New +786,236 | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $615.6k | 730,000 | | Unchanged | | [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $504.1k | 597,729 | | Added +443,631 | | [Lynx1 Capital Management LP](/funds/1910456.md) | 2026-06-30 | $471.8k | 559,470 | | Added +544,392 | | [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $403.2k | 478,142 | | Reduced −200,000 | | [SPHERA FUNDS MANAGEMENT LTD.](/funds/1496201.md) | 2026-06-30 | $336.0k | 398,486 | | New +398,486 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $278.2k | 330,049 | | Added +274,856 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $182.2k | 216,006 | | Added +194,765 | | [Alyeska Investment Group, L.P.](/funds/1453072.md) | 2026-06-30 | $138.6k | 164,376 | | New +164,376 | ## Recent filings [All 971 filings](/companies/traw/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-23 | 17:18 ET | [8-K](/filings/0001104659-26-118519.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001104659-26-118519 | | 2026-10-20 | 16:05 ET | [DEF 14A](/filings/0001104659-26-117406.md) | Proxy statement, period 2026-12-03 | 0001104659-26-117406 | | 2026-08-14 | 16:35 ET | [10-Q](/filings/0001104659-26-097261.md) | Quarterly report, period 2026-06-30 | 0001104659-26-097261 | | 2026-08-14 | 16:30 ET | [8-K](/filings/0001104659-26-097226.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-097226 | | 2026-07-31 | 16:15 ET | [8-K](/filings/0001104659-26-089220.md) | 3.01 Delisting notice | 0001104659-26-089220 | | 2026-07-10 | 16:02 ET | [8-K](/filings/0001104659-26-082649.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-082649 | | 2026-07-09 | 16:01 ET | [8-K](/filings/0001104659-26-082250.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-082250 | | 2026-06-22 | 07:00 ET | [8-K](/filings/0001104659-26-076058.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-076058 | | 2026-06-12 | 17:25 ET | [8-K](/filings/0001104659-26-073593.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-073593 | | 2026-05-29 | 09:00 ET | [DEF 14A](/filings/0001104659-26-067945.md) | Proxy statement, period 2026-07-08 | 0001104659-26-067945 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-043832.md), filed Apr 15, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1130598 - Tickers: TRAW - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 16:48 ET. No prices; not investment advice.